InvestorsHub Logo
Followers 58
Posts 2505
Boards Moderated 0
Alias Born 09/21/2009

Re: EM post# 5161

Sunday, 01/15/2017 3:16:11 PM

Sunday, January 15, 2017 3:16:11 PM

Post# of 8449
In general. I think it's almost the perfect acquisition for Ktov. Price paid, combination drug, market potential, ect... my only concern is cash. Which a licensing deal would take care of no problem, say 20 million upfront. I'm thinking our 18million took some nice whack downs recently. 2 million renal study, 2 million acquisition, 2 million for last 6 month operating expenses plus attorney fees for acquisition. Maybe I'm wrong but I put cash around 10-12 million. Which is still good for having no debt. But, if no deal on kit in 3 months will they be tempted to do another offering to help fund new trials and operating expenses. That's my only concern here. Other than that. Acquisition was good, imo.